Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.
Combined structural and functional patterns discriminating upper limb motor disability in multiple sclerosis using multivariate approaches.
Enhancement of Chemotactic Cell Aggregation by Haptotactic Cell-To-Cell Interaction.
The effects of diet on the severity of central nervous system disease: One part of lab-to-lab variability.
Glial cells as drug targets: What does it take?
Headwaters of the zebrafish -- emergence of a new model vertebrate.
Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results.
No association between genetic polymorphism at codon 129 of the prion protein gene and primary progressive multiple sclerosis.
Estrogen treatment in multiple sclerosis.
Antibody producing B lineage cells invade the central nervous system predominantly at the time of and triggered by acute Epstein-Barr virus infection: A hypothesis on the origin of intrathecal immunoglobulin synthesis in multiple sclerosis.
Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9.
Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.
Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica.
New data from Phase 3 studies provide additional evidence supporting treatment effect for oral BG-12 (dimethyl fumarate) in multiple sclerosis
Mylan's ANDA for Three Times Per Week Generic Copaxone® 40 mg/mL Accepted for Filing by FDA
Repurposing drugs for disease modification in multiple sclerosis
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
Gordon Research Conference on In Vivo Magnetic Resonance
The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis.
National MS Society: Ralph I. Straus Award
Beneficial actions of the anti-inflammatory dimethyl fumarate in glioblastomas.
Paucity and Inconsistency: A Systematic Review and Critique of Budget Impact Analyses of Disease-Modifying Therapies for Multiple Sclerosis in the UK and the Implications for Policy in the UK.
Widespread cortical thinning in patients with neuromyelitis optica spectrum disorder.
Evaluation of pattern-reversal visual evoked potential in patients with neuromyelitis optica.
Pages
« first
‹ previous
…
85
86
87
88
89
90
91
92
93
…
next ›
last »